STAAR Surgical Files DEFA14A

Ticker: STAA · Form: DEFA14A · Filed: Sep 26, 2025 · CIK: 718937

Staar Surgical Co DEFA14A Filing Summary
FieldDetail
CompanyStaar Surgical Co (STAA)
Form TypeDEFA14A
Filed DateSep 26, 2025
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$28.00, $313.9 M, $15.09, $20.27, $500m
Sentimentneutral

Sentiment: neutral

Topics: proxy-statement, sec-filing, additional-materials

TL;DR

STAAR Surgical filed additional proxy materials, no fee required.

AI Summary

STAAR Surgical Company filed a Definitive Additional Materials (DEFA14A) on September 26, 2025. This filing indicates no fee was required for this submission. The company, incorporated in Delaware with its principal office in Monrovia, California, operates in the ophthalmic goods sector.

Why It Matters

This filing is a routine proxy statement, indicating the company is providing updated or additional materials to shareholders regarding corporate matters, which could include upcoming shareholder votes or disclosures.

Risk Assessment

Risk Level: low — This filing is a standard DEFA14A, which typically contains routine corporate disclosures and does not inherently signal significant new risks.

Key Players & Entities

  • STAAR SURGICAL COMPANY (company) — Registrant
  • 0001193125-25-219844 (filing_id) — Accession Number
  • 20250926 (date) — Filing Date
  • Monrovia, CA 91016 (location) — Business Address

FAQ

What type of filing is this DEFA14A for STAAR Surgical Company?

This filing is classified as Definitive Additional Materials, indicated by the checkbox next to 'Definitive Additional Materials' being selected.

When was this DEFA14A filed with the SEC?

The filing was made on September 26, 2025.

Is there a filing fee associated with this DEFA14A?

No, the filing indicates that no fee was required, as the checkbox next to 'No fee required' is selected.

What is the primary business of STAAR Surgical Company?

STAAR Surgical Company is in the Ophthalmic Goods industry, with SIC code 3851.

Where is STAAR Surgical Company's principal place of business located?

The company's business address is 1911 Walker Ave, Monrovia, CA 91016.

Filing Stats: 4,423 words · 18 min read · ~15 pages · Grade level 15.5 · Accepted 2025-09-26 11:52:17

Key Financial Figures

  • $28.00 — est Path Forward for STAAR Stockholders $28.00 per share all-cash consideration provid
  • $313.9 M — STAAR Surgical Overview FY24 Net Sales $313.9 M FY24 Net Loss $(20.2) M FY20-FY25 Net S
  • $15.09 — esults, STAAR's stock price declined to $15.09 and traded in the range of $15.09 to $2
  • $20.27 — 09 and traded in the range of $15.09 to $20.27 through the date of the Alcon merger an
  • $500m — ounced since 2015 with deal value above $500mm. $28.00 per share all-cash considerati
  • $19 — median sellside analyst price target of $19(3) median premium paid in comparable tr
  • $18 — ansactions(4) premium to 90-Day VWAP of $18(1) premium to unaffected share price(2)
  • $14.5M — ket check with nominal break-up fees of $14.5M (1%) for certain proposals received dur
  • $43.4M — during 45-day "window shop" period and $43.4M (3%) for proposals received thereafter
  • $72M — lity, Alcon regulatory commitments, and $72M (5%) break-up fee payable by Alcon to S
  • $18.49 — ard O P $28.00 per share all-cash offer $18.49 per share prior to announcement If the

Filing Documents

Forward-Looking Statements

Forward-Looking Statements The information covered by this communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often contain words such as "anticipate," "believe," "expect," "plan," "estimate," "project," "continue," "will," "should," "may," and similar terms. All statements in this communication that are not performance or achievements to be materially different from what is expressed or implied by the forward-looking statements, including, but not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Alcon merger agreement or could cause the consummation of the proposed transaction to be delayed or to fail to occur; (2) the failure to obtain approval of the proposed transaction from STAAR's stockholders; (3) the failure to obtain certain required regulatory approvals or the failure to satisfy any of the other closing conditions to the completion of the proposed transaction within the expected timeframes or at all; (4) risks related to disruption of management's attention from STAAR's ongoing business operations due to the proposed transaction; (5) the effect of the announcement of the proposed transaction on the ability of STAAR to retain and hire key personnel and maintain relationships with its customers, suppliers and others with whom it does business, or on its operating results and business generally; (6) the ability of STAAR to meet expectations regarding the timing and completion of the transaction; (7) the outcome of any legal proceedings that may be instituted against STAAR related to the proposed transaction; (8) the possibility that STAAR's stock pr

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. STAAR Surgical Company Date: September 26, 2025 By: /s/ Stephen C. Farrell Name: Stephen C. Farrell Title: Chief Executive Officer Alcon Merger Maximizes Value for Stockholders of STAAR Surgical September 2025 Exhibit 99.1 Additional Information About the Merger and Where to Find It This presentation relates to the proposed transaction (the "Alcon merger") involving STAAR Surgical Company ("STAAR", "us" or "our"), Alcon Research, LLC, a Delaware limited liability company ("Alcon"), and Rascasse Merger Sub, Inc., a Delaware corporation and a wholly owned direct subsidiary of Alcon ("Merger Sub"). In connection with the proposed transaction, STAAR has filed relevant materials with the U.S. Securities and Exchange Commission (the "SEC"), including STAAR's definitive proxy statement on Schedule 14A (the "Proxy Statement"), on September 16, 2025. The Proxy Statement was first sent to STAAR stockholders on September 16, 2025. This presentation is not a substitute for the Proxy Statement or any other document that STAAR may file with the SEC or send to its stockholders in connection with the proposed transaction. BEFORE MAKING ANY VOTING DECISION, STOCKHOLDERS OF STAAR ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, INCLUDING THE PROXY STATEMENT, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO, IN CONNECTION WITH THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain the documents (when available) free of charge at the SEC's website, www.sec.gov, or by visiting STAAR's investor relations website, https://investors.staar.com. No Offer or Solicitation This presentation is for informational purposes only an

View Full Filing

View this DEFA14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.